Skip to main content
. Author manuscript; available in PMC: 2013 Jun 4.
Published in final edited form as: Lancet. 2011 Nov 15;379(9810):39–46. doi: 10.1016/S0140-6736(11)61226-9

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Kaplan-Meier Curves of Key Efficacy Endpoints

Panel A shows the primary endpoint of bone metastasis-free survival. Panels B and C show the time to bone metastases (asymptomatic or symptomatic) and time to symptomatic bone metastasis, respectively. Panel D shows overall survival.

Note: All curves were truncated when the combined risk sets dropped to below 3.5% of the total risk set (i.e., when there were 50 patients or less in the combined risk sets).